ARTICLE | Clinical News
CytRx preclinical data
July 15, 2013 7:00 AM UTC
In animal xenograft models of human GBM, aldoxorubicin significantly reduced tumor growth and more than doubled the mean survival time vs. both doxorubicin and placebo (p<0.0001). CytRx also said that uptake of the compound was confined only to the tumor in the brain and did not enter normal brain tissue. Data will be presented at the European Society for Medical Oncology meeting in Amsterdam in September. This year, CytRx plans to start a Phase IIb trial of aldoxorubicin to treat relapsed GBM. ...